COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Pregnancy Outcome Following Global Fibroid Ablation Using the Acessa™ System

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03028610
Recruitment Status : Recruiting
First Posted : January 23, 2017
Last Update Posted : February 11, 2020
Information provided by (Responsible Party):
University Women's Hospital Tübingen

Brief Summary:
Prospective, interventional, single-center, longitudinal, single-arm pilot study to evaluate pregnancies following the Acessa™ treatment of uterine myomas in women who desire future childbearing

Condition or disease Intervention/treatment Phase
One or More Uterine Fibroids Device: radiofrequency generator Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pregnancy Outcome Following Global Fibroid Ablation Using the Acessa™ System
Study Start Date : January 2016
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : April 2021

Arm Intervention/treatment
Experimental: Acessa™ System
radiofrequency generator
Device: radiofrequency generator

Primary Outcome Measures :
  1. Spontaneous abortion [ Time Frame: 6 months ]
  2. Ectopic pregnancy [ Time Frame: three years ]
  3. Vaginal delivery and either [ Time Frame: three years ]

    i. Uncomplicated delivery or ii. Delivery with complications such as:

    • Premature rupture of the membranes (PROM) or
    • Preterm premature rupture of the membranes (PPROM)

  4. Caesarean section delivery and either [ Time Frame: three years ]

    i. Uncomplicated delivery or ii. Delivery with complications such as:

    • Preterm delivery
    • Preterm labor
    • Uterine rupture
    • Stillbirths
    • Postpartum

Secondary Outcome Measures :
  1. Procedure-related complications within 1 month post-procedure [ Time Frame: 1 month ]
  2. Post-treatment readmission and reintervention rate within 1 month post-procedure assessed by questionnairie [ Time Frame: 1 month ]
  3. Post-treatment changes in menstrual status up to 36 months post-procedure assessed by a menstrual impact score [ Time Frame: three years ]
  4. Post-treatment changes in myoma size as determined by ultrasound [ Time Frame: 3, 6, 36 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Are premenopausal and aged 18 to 40 years.
  2. Have already consented to have their fibroids treated with the Acessa™ procedure.
  3. Desire pregnancy within two years following Acessa™ treatment
  4. Have a normal endometrial cavity as delineated by sonohysterogram within 6 months prior to treatment.
  5. Have a uterine size relating to ≤14 weeks of pregnancy, as determined by palpatory pelvic exam.
  6. Have fibroids identified by transvaginal ultrasound with:

    1. ≤6 (six) fibroids of ≤5 cm at the major diameter
    2. a total uterine volume of no greater than 300 cc
  7. Patients with type 2 fibroids are acceptable for inclusion.
  8. Are current in their screening for cervical cancer precursors (i.e. PAP 1 or 2).
  9. Are capable of providing informed consent.
  10. Are willing and able to comply with all study tests, procedures, and assessment tools during screening and up to 3 years post treatment.
  11. Are able to pass a pre-operative health exam (ASA I-III).
  12. Patients who are currently undergoing fertility treatments (e.g. Clomid, IVF, etc.) or who are planning such treatments may be enrolled in the study.

Exclusion Criteria:

  1. Have contraindications for laparoscopic surgery and/or general anesthesia.
  2. Have cervical myomas or Type 0 or Type 1 myomas. Type 0 and Type 1 myomas are excluded as these are generally accessible to hysteroscopic approaches. Cervical myomas are difficult to treat and present a greater risk of bladder or urethral injury.
  3. Have one or more Type 0 (completely intracavitary) or Type 1 resectable submucous fibroids.
  4. Have known or suspected abdominal adhesions which are expected to complicate laparoscopic surgery.
  5. Have known or suspected untreated intra-uterine adhesions or uterine septum.
  6. Have previously undergone endometrial ablation, uterine artery embolization, or uterine artery ligation/occlusion, high-intensity focused ultrasound, laparoscopic, hysteroscopic or abdominal myomectomy, or any other uterine-preserving technique for reduction of menstrual bleeding.
  7. Subjects taking platelet-inhibiting drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, and clopidogrel
  8. Are pregnant or lactating.
  9. Have known or suspected severe endometriosis.
  10. Have known or suspected adenomyosis.
  11. Have active or history of pelvic inflammatory disease.
  12. Have a history of or evidence of gynecologic malignancy or pre-malignancy within the past five years.
  13. Have had pelvic radiation.
  14. Have a persistent and undiagnosed complex adnexal mass.Are unable to give informed consent.
  15. In the medical judgment of the investigator should not participate in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03028610

Layout table for location contacts
Contact: Sara Y Brucker, MD 0049707180791

Layout table for location information
University Women's Hospital Recruiting
Tübingen, Germany, 72076
Contact: Bernhard Krämer, MD    0049707182211   
Sponsors and Collaborators
University Women's Hospital Tübingen
Layout table for investigator information
Principal Investigator: Sara Y Brucker, MD University Women's Hospital, Calwerstrasse 7, 72076 Tübingen, Germany
Layout table for additonal information
Responsible Party: University Women's Hospital Tübingen Identifier: NCT03028610    
Other Study ID Numbers: GFA-001
First Posted: January 23, 2017    Key Record Dates
Last Update Posted: February 11, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Connective Tissue Diseases